Evaluation of 18F-dopa and 123I-MIBG Uptake in the Patients With Neuroblastoma

The Evaluation of the 6-[18F]Fluoro-levo-dopa and 123I-MIBG Uptake in the Patients With Neuroblastoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01943097

Enrollment

160

Registered

2013-09-16

Start date

2007-06-30

Completion date

2014-12-31

Last updated

2014-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroblastoma

Brief summary

Neuroblastic tumors are childhood neoplasms that possess amino acid decarboxylase (AADC) activity and Meta-iodobenzylguanidine(MIBG), they can theoretically be imaged by (18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) and (123)I-Meta-iodobenzylguanidine((123)I-MIBG) PET, they are new and specific diagnostic and follow-up tools for neuroendocrine tumors. In this study, we explored the accuracy and clinical role of (18)F-FDOPA and (123)I-MIBG PET in neuroblastic tumors. METHODS: Patients with tissue-proven neuroblastic tumors receiving (18)F-FDOPA PET or (123)I-MIBG at initial diagnosis or during follow-ups were enrolled. The sensitivity and specificity of (18)F-FDOPA or (123)I-MIBG PET were compared to each other and compared to(18)F-FDG PET, using tumor histology as the standard.

Interventions

None listed

Study design

Observational model

CASE_CROSSOVER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

No minimum to 30 Years

Healthy volunteers

Inclusion criteria

* (1) Diagnosed by clinical criteria(one of below) 1. Proved as Neuroblastoma by a pathological section 2. Bone meta with 24 hrs urine VMA(Vanillylmandelic acid )or HVA (Homovanillic acid) elevated 3. CT or MRI found tumor around adrenal gland or Neuroblastic tumor * (2) Age between 0-30 years old，Body weight over 2.5kg * (3) Signed Inform Consent Form

Exclusion criteria

* (1)AST and ALT \> 200U/L、Cre \> 2.5mg/dl * (2)Allerg to 18F-dopa、123I-MIBG * (3)Subject not fit this study(assessed by PI) * (4)No more need to arrenge PET because disease progress, assessed by VS

Design outcomes

Primary

Measure	Time frame	Description
The maximum standardized uptake value and tumor-to-liver uptake ratio	Outcome will be measured in one week after performed.	The maximum standardized uptake value and tumor-to-liver uptake ratio will be evaluated by specific Nuclear Medicine doctor.

Countries

Taiwan

Outcome results